This text is a result of machine translation.
Zelensky called on the international community to provide funds for Ukraine's reconstruction, which is expected to cost $500 billion
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
913 companies have been investigated by public funds since the second quarter, and the six top flow fund managers focus on the leaders of subdivided industries
Chinese Retail Firm Meituan’s Revenue Sees 26.7% Bump in Q1 2023, Reaching CNY 58.6 Bn
In the first quarter of 2023, Meituan continued to further promote its "Retail + Technology" strategy to increase its investment in China's consumer market, with R&D spending increasing to CNY 5 billion.
May 26, 2023 04:01 PM
Chinese Carmaker Xpeng’s Revenue in Q1 2023 Exceeds CNY 4.03 Bn, Down 45.9% YoY
The G6 will be officially released in June, with mass deliveries beginning in July and rapidly increasing. The G6 is expected to propel Xpeng's overall deliveries to a much above-industry growth rate in the third quarter, representing the first sales inflection point following Xpeng's strategic and organizational improvements.
May 25, 2023 03:13 PM
A number of enterprises on the science and innovation board are listed on the "white list" of key enterprises for operation guarantee and transfer
China’s Smartphone Giant Xiaomi's Revenue in Q1 2023 Exceeds CNY 59.48 Bn, Down 18.9% YoY
In 2023, Xiaomi’s overall business mode will shift from scale expansion to quality enhancement. According to the financial report for Q1 2023, Xiaomi's overall inventory amounted to CNY 42.6 billion, a decrease of over 24% from the same period last year, achieving three consecutive quarters of decline, and the lowest level in the past nine quarters.
May 25, 2023 03:00 PM
Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab
The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.
Sep 20, 2022 03:35 PM
Fengtai District of Beijing will lift the epidemic prevention zone of the whole region from now on.
Hong Kong stocks continued to rise in the anti epidemic sector, and Junshi biology rose nearly 17%
TOPS in Shanghai: The New Trends in the Pet Industry's Overseas Expansion
May 12, 2023 01:33 PM